What is CRISPR Therapeutics's treasury stock?

CRISPR Therapeutics (CRSP) reported treasury stock of $60K in Q1 2026.

How has CRISPR Therapeutics's treasury stock changed year-over-year?

CRISPR Therapeutics's treasury stock decreased by 3.2% year-over-year, from $62K to $60K.

What is the long-term trend for CRISPR Therapeutics's treasury stock?

Over 5 years (2020 to 2025), CRISPR Therapeutics's treasury stock has grown at a -1.0% compound annual growth rate (CAGR), from $63K to $60K.

What does treasury stock mean?

Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

CRISPR Therapeutics CRSP Treasury Stock

Treasury Stock at other companies

Arrowhead ResearchARWR

$53.19M—

BridgeBio PharmaBBIO

$405.78M+25.5%

Regeneron PharmaceuticalsREGN

$19.41B+19.7%

BiogenBIIB

$2.98B0.0%

Johnson & JohnsonJNJ

$76.26B+0.5%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's treasury stock?: CRISPR Therapeutics (CRSP) reported treasury stock of $60K in Q1 2026.
How has CRISPR Therapeutics's treasury stock changed year-over-year?: CRISPR Therapeutics's treasury stock decreased by 3.2% year-over-year, from $62K to $60K.
What is the long-term trend for CRISPR Therapeutics's treasury stock?: Over 5 years (2020 to 2025), CRISPR Therapeutics's treasury stock has grown at a -1.0% compound annual growth rate (CAGR), from $63K to $60K.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.